(Q40525696)

English

A prospective, randomized study comparing cefepime and imipenem-cilastatin in the empirical treatment of febrile neutropenia in patients treated for haematological malignancies

scientific article published on January 2004

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

A prospective, randomized study comparing cefepime and imipenem-cilastatin in the empirical treatment of febrile neutropenia in patients treated for haematological malignancies (English)

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

5

object named as

Per Ljungman

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

author name string

Honar Cherif

1

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Magnus Björkholm

2

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Per Engervall

3

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Peter Johansson

4

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Robert Hast

6

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Mats Kalin

7

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

publication date

1 January 2004

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Infectious Diseases

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

36

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

593-600

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

A randomized study of imipenem compared to cefotaxime plus piperacillin as initial therapy of infections in granulocytopenic patients

1 reference

https://api.crossref.org/works/10.1080%2F00365540410017590

21 January 2018

A meta-analysis of clinical studies of imipenem-cilastatin for empirically treating febrile neutropenic patients

1 reference

https://api.crossref.org/works/10.1080%2F00365540410017590

21 January 2018

2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer

1 reference

https://api.crossref.org/works/10.1080%2F00365540410017590

21 January 2018

Single-drug versus combination empirical therapy for gram-negative bacillary infections in febrile cancer patients with and without granulocytopenia

1 reference

https://api.crossref.org/works/10.1080%2F00365540410017590

21 January 2018

A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia

1 reference

https://api.crossref.org/works/10.1080%2F00365540410017590

21 January 2018

Cefepime or carbapenem treatment for febrile neutropenia as a single agent is as effective as a combination of 4th-generation cephalosporin + aminoglycosides: comparative study

1 reference

https://api.crossref.org/works/10.1080%2F00365540410017590

21 January 2018

Cefepime plus amikacin versus piperacillin-tazobactam plus amikacin for initial antibiotic therapy in haematology patients with febrile neutropenia: results of an open, randomized, multicentre trial

1 reference

https://api.crossref.org/works/10.1080%2F00365540410017590

21 January 2018

Comparison of cefepime versus ceftriaxone-amikacin as empirical regimens for the treatment of febrile neutropenia in acute leukemia patients

1 reference

https://api.crossref.org/works/10.1080%2F00365540410017590

21 January 2018

Cefepime versus ceftazidime as empiric therapy for fever in neutropenic patients with cancer

1 reference

https://api.crossref.org/works/10.1080%2F00365540410017590

21 January 2018

Cefepime/amikacin versus ceftazidime/amikacin as empirical therapy for febrile episodes in neutropenic patients: a comparative study. The French Cefepime Study Group.

1 reference

https://api.crossref.org/works/10.1080%2F00365540410017590

21 January 2018

Comparison of cefepime and ceftazidime in combination with amikacin in the empirical treatment of high-risk patients with febrile neutropenia: a prospective, randomized, multicenter study

1 reference

https://api.crossref.org/works/10.1080%2F00365540410017590

21 January 2018

Randomized comparison of cefepime and ceftazidime for treatment of skin, surgical wound, and complicated urinary tract infections in hospitalized subjects

1 reference

https://api.crossref.org/works/10.1080%2F00365540410017590

21 January 2018

In vitro evaluation of cefepime and other broad-spectrum beta-lactams in 22 medical centers in Japan: a phase II trial comparing two annual organism samples. The Japan Antimicrobial Resistance Study Group.

1 reference

https://api.crossref.org/works/10.1080%2F00365540410017590

21 January 2018

Treatment of febrile neutropenic patients with cancer who require hospitalization: a prospective randomized study comparing imipenem and cefepime

1 reference

https://api.crossref.org/works/10.1080%2F00365540410017590

21 January 2018

Risk factors for recurrent fever after the discontinuation of empiric antibiotic therapy for fever and neutropenia in pediatric patients with a malignancy or hematologic condition

1 reference

https://api.crossref.org/works/10.1080%2F00365540410017590

21 January 2018

Secular trends in mortality associated with bloodstream infections in 4268 patients hospitalized in a cancer referral center between 1975 and 1989.

1 reference

https://api.crossref.org/works/10.1080%2F00365540410017590

21 January 2018

Trimethoprim-Sulfamethoxazole plus Amikacin as First-Line Therapy and Imipenem/Cilastatin as Second Empirical Therapy in Febrile Neutropenic Patients with Hematological Disorders

1 reference

https://api.crossref.org/works/10.1080%2F00365540410017590

21 January 2018

Cefepime as empirical monotherapy in febrile patients with hematological malignancies and neutropenia: a randomized, single-center phase II trial

1 reference

https://api.crossref.org/works/10.1080%2F00365540410017590

21 January 2018

The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients.

1 reference

https://api.crossref.org/works/10.1080%2F00365540410017590

21 January 2018

Antimicrobial therapy of unexplained fever in neutropenic patients--guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO), Study Group Interventional Therapy of Unexplained Fever, Arbeits

1 reference

https://api.crossref.org/works/10.1080%2F00365540410017590

21 January 2018

Identifiers

10.1080/00365540410017590

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40525696&oldid=1899898816"